Expression of p27(kip1) in prostatic adenocarcinoma

John C. Cheville, Ricardo V. Lloyd, Thomas J. Sebo, Liang Cheng, Lori Erickson, David G. Bostwick, Christine M. Lohse, Peter Wollan

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

p27(kip1) (p27) protein is an inhibitor of cyclin and cyclin-dependent kinase complexes and prevents progression of cells from G1 to the S phase of the cell cycle. p27 might have tumor suppressor activity, and decreased p27 expression is associated with aggressive tumor in several human malignancies. The object of this study was to evaluate p27 expression in prostatic adenocarcinoma treated by radical prostatectomy and to assess its association with numerous morphologic and clinical features. One hundred thirty-eight prostatic adenocarcinomas were evaluated for p27 expression by quantifying immunohistochemical staining. p27 expression was tested for association with patient age, family history of prostate cancer, preoperative serum prostate- specific antigen level, Gleason score, extraprostatic extension, seminal vesicle involvement, lymph node metastases, tumor-node-metastasis stage, DNA ploidy by flow cytometric analysis, and subclinical biochemical failure. p27 expression was analyzed as a continuous variable, and we also classified the tumors as low expressors (<50% of cells p27 positive) or high expressors (> 50% of cells p27 positive) for comparison. Patients with adenocarcinomas that exhibited low p27 expression had higher mean Gleason scores than did high expressors (7 vs. 6.2, respectively; P = .002). Low p27 expression correlated with positive surgical margins (P = .05), seminal vesicle involvement (P = .007), lymph node metastasis (P = .03), and aneuploid cancers (P = .003), but it did not correlate with subclinical biochemical failure. p27 expression correlated with a number of prognostic morphologic features in prostatic adenocarcinoma, and the evaluation of p27 expression might provide additional prognostic information.

Original languageEnglish (US)
Pages (from-to)324-328
Number of pages5
JournalModern Pathology
Volume11
Issue number4
StatePublished - Apr 1998
Externally publishedYes

Fingerprint

Adenocarcinoma
Neoplasms
Neoplasm Grading
Seminal Vesicles
Neoplasm Metastasis
Lymph Nodes
Cyclin-Dependent Kinase Inhibitor p27
Cyclins
Cyclin-Dependent Kinases
Ploidies
Aneuploidy
Prostate-Specific Antigen
Prostatectomy
S Phase
Prostatic Neoplasms
Cell Cycle
Staining and Labeling
DNA
Serum

Keywords

  • Adenocarcinoma
  • p27
  • Prostate
  • Sub-clinical biochemical failure

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Cheville, J. C., Lloyd, R. V., Sebo, T. J., Cheng, L., Erickson, L., Bostwick, D. G., ... Wollan, P. (1998). Expression of p27(kip1) in prostatic adenocarcinoma. Modern Pathology, 11(4), 324-328.

Expression of p27(kip1) in prostatic adenocarcinoma. / Cheville, John C.; Lloyd, Ricardo V.; Sebo, Thomas J.; Cheng, Liang; Erickson, Lori; Bostwick, David G.; Lohse, Christine M.; Wollan, Peter.

In: Modern Pathology, Vol. 11, No. 4, 04.1998, p. 324-328.

Research output: Contribution to journalArticle

Cheville, JC, Lloyd, RV, Sebo, TJ, Cheng, L, Erickson, L, Bostwick, DG, Lohse, CM & Wollan, P 1998, 'Expression of p27(kip1) in prostatic adenocarcinoma', Modern Pathology, vol. 11, no. 4, pp. 324-328.
Cheville JC, Lloyd RV, Sebo TJ, Cheng L, Erickson L, Bostwick DG et al. Expression of p27(kip1) in prostatic adenocarcinoma. Modern Pathology. 1998 Apr;11(4):324-328.
Cheville, John C. ; Lloyd, Ricardo V. ; Sebo, Thomas J. ; Cheng, Liang ; Erickson, Lori ; Bostwick, David G. ; Lohse, Christine M. ; Wollan, Peter. / Expression of p27(kip1) in prostatic adenocarcinoma. In: Modern Pathology. 1998 ; Vol. 11, No. 4. pp. 324-328.
@article{5ba9c824c7754388a06e334dbf5214e1,
title = "Expression of p27(kip1) in prostatic adenocarcinoma",
abstract = "p27(kip1) (p27) protein is an inhibitor of cyclin and cyclin-dependent kinase complexes and prevents progression of cells from G1 to the S phase of the cell cycle. p27 might have tumor suppressor activity, and decreased p27 expression is associated with aggressive tumor in several human malignancies. The object of this study was to evaluate p27 expression in prostatic adenocarcinoma treated by radical prostatectomy and to assess its association with numerous morphologic and clinical features. One hundred thirty-eight prostatic adenocarcinomas were evaluated for p27 expression by quantifying immunohistochemical staining. p27 expression was tested for association with patient age, family history of prostate cancer, preoperative serum prostate- specific antigen level, Gleason score, extraprostatic extension, seminal vesicle involvement, lymph node metastases, tumor-node-metastasis stage, DNA ploidy by flow cytometric analysis, and subclinical biochemical failure. p27 expression was analyzed as a continuous variable, and we also classified the tumors as low expressors (<50{\%} of cells p27 positive) or high expressors (> 50{\%} of cells p27 positive) for comparison. Patients with adenocarcinomas that exhibited low p27 expression had higher mean Gleason scores than did high expressors (7 vs. 6.2, respectively; P = .002). Low p27 expression correlated with positive surgical margins (P = .05), seminal vesicle involvement (P = .007), lymph node metastasis (P = .03), and aneuploid cancers (P = .003), but it did not correlate with subclinical biochemical failure. p27 expression correlated with a number of prognostic morphologic features in prostatic adenocarcinoma, and the evaluation of p27 expression might provide additional prognostic information.",
keywords = "Adenocarcinoma, p27, Prostate, Sub-clinical biochemical failure",
author = "Cheville, {John C.} and Lloyd, {Ricardo V.} and Sebo, {Thomas J.} and Liang Cheng and Lori Erickson and Bostwick, {David G.} and Lohse, {Christine M.} and Peter Wollan",
year = "1998",
month = "4",
language = "English (US)",
volume = "11",
pages = "324--328",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Expression of p27(kip1) in prostatic adenocarcinoma

AU - Cheville, John C.

AU - Lloyd, Ricardo V.

AU - Sebo, Thomas J.

AU - Cheng, Liang

AU - Erickson, Lori

AU - Bostwick, David G.

AU - Lohse, Christine M.

AU - Wollan, Peter

PY - 1998/4

Y1 - 1998/4

N2 - p27(kip1) (p27) protein is an inhibitor of cyclin and cyclin-dependent kinase complexes and prevents progression of cells from G1 to the S phase of the cell cycle. p27 might have tumor suppressor activity, and decreased p27 expression is associated with aggressive tumor in several human malignancies. The object of this study was to evaluate p27 expression in prostatic adenocarcinoma treated by radical prostatectomy and to assess its association with numerous morphologic and clinical features. One hundred thirty-eight prostatic adenocarcinomas were evaluated for p27 expression by quantifying immunohistochemical staining. p27 expression was tested for association with patient age, family history of prostate cancer, preoperative serum prostate- specific antigen level, Gleason score, extraprostatic extension, seminal vesicle involvement, lymph node metastases, tumor-node-metastasis stage, DNA ploidy by flow cytometric analysis, and subclinical biochemical failure. p27 expression was analyzed as a continuous variable, and we also classified the tumors as low expressors (<50% of cells p27 positive) or high expressors (> 50% of cells p27 positive) for comparison. Patients with adenocarcinomas that exhibited low p27 expression had higher mean Gleason scores than did high expressors (7 vs. 6.2, respectively; P = .002). Low p27 expression correlated with positive surgical margins (P = .05), seminal vesicle involvement (P = .007), lymph node metastasis (P = .03), and aneuploid cancers (P = .003), but it did not correlate with subclinical biochemical failure. p27 expression correlated with a number of prognostic morphologic features in prostatic adenocarcinoma, and the evaluation of p27 expression might provide additional prognostic information.

AB - p27(kip1) (p27) protein is an inhibitor of cyclin and cyclin-dependent kinase complexes and prevents progression of cells from G1 to the S phase of the cell cycle. p27 might have tumor suppressor activity, and decreased p27 expression is associated with aggressive tumor in several human malignancies. The object of this study was to evaluate p27 expression in prostatic adenocarcinoma treated by radical prostatectomy and to assess its association with numerous morphologic and clinical features. One hundred thirty-eight prostatic adenocarcinomas were evaluated for p27 expression by quantifying immunohistochemical staining. p27 expression was tested for association with patient age, family history of prostate cancer, preoperative serum prostate- specific antigen level, Gleason score, extraprostatic extension, seminal vesicle involvement, lymph node metastases, tumor-node-metastasis stage, DNA ploidy by flow cytometric analysis, and subclinical biochemical failure. p27 expression was analyzed as a continuous variable, and we also classified the tumors as low expressors (<50% of cells p27 positive) or high expressors (> 50% of cells p27 positive) for comparison. Patients with adenocarcinomas that exhibited low p27 expression had higher mean Gleason scores than did high expressors (7 vs. 6.2, respectively; P = .002). Low p27 expression correlated with positive surgical margins (P = .05), seminal vesicle involvement (P = .007), lymph node metastasis (P = .03), and aneuploid cancers (P = .003), but it did not correlate with subclinical biochemical failure. p27 expression correlated with a number of prognostic morphologic features in prostatic adenocarcinoma, and the evaluation of p27 expression might provide additional prognostic information.

KW - Adenocarcinoma

KW - p27

KW - Prostate

KW - Sub-clinical biochemical failure

UR - http://www.scopus.com/inward/record.url?scp=0031596542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031596542&partnerID=8YFLogxK

M3 - Article

C2 - 9578081

AN - SCOPUS:0031596542

VL - 11

SP - 324

EP - 328

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 4

ER -